| 查看: 327 | 回复: 2 | |||
| 当前主题已经存档。 | |||
徐亚萍金虫 (正式写手)
|
[交流]
新药-比伐卢定 大家讨论一下
|
||
|
比伐卢定:这种药除了上海子能制药还有别的生产厂家吗？它与蛇毒凝血酶是不是一种东西， 比伐卢定 [128270-60-0] Purity (HPLC) ≥98% D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu 合成工艺：Monograph Number: 1306 Title: Bivalirudin CAS Registry Number: 128270-60-0 Additional Names: Hirulog-1; hirulog-8 Manufacturers' Codes: BG-8967 Trademarks: Angiomax (Medicines Co.); Hirulog (Biogen) Molecular Formula: C98H138N24O33 Molecular Weight: 2180.28. Percent Composition: C 53.99%, H 6.38%, N 15.42%, O 24.22% Literature References: Synthetic peptide of 20 amino acids; member of a novel class of bivalent thrombin inhibitors. Characterized by an anion binding exosite (ABE) derived from hirudin, q.v., linked to a thrombin catalytic site inhibitor moiety by tetraglycine. Prepn and structure activity study: J. M. Maraganore et al., WO 91 02750; eidem, US 5196404 (1991, 1993 both to Biogen); eidem, Biochemistry 29, 7095 (1990). Determn in plasma and whole blood: T. J. Reid, B. M. Alving, Thromb. Haemostasis 70, 608 (1993). Clinical pharmacology: I. Fox et al., ibid. 69, 157 (1993). Clinical study in myocardial infarction: P. Théroux et al., Circulation 91, 2132 (1995); during coronary angioplasty: J. A. Bittl et al., N. Engl. J. Med. 333, 764 (1995). Review of antithrombotic activity and clinical evaluation: J. M. Maraganore, Perspect. Drug Discovery Design 1, 461-478 (1993). Therap-Cat: Antithrombotic. RCB_CT,74865Entry Name: Bivalirudin, BAN, INN, USAN Synonym(s): Hirulog I. Angiomax. BG 8967 Chapman Hall Number: NCZ48-N CAS Registry Number: 128270-60-0 Type of Compound Code(s): XA2290 XA4500 XA1350 H-D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH Molecular Formula: C98H138N24O33 Molecular Weight: 2180.309 Accurate Mass: 2178.985821 Percentage Composition: C 53.99%; H 6.38%; N 15.42%; O 24.22% Biological Use/Importance: Anticoagulant. Haemostatic agent Development Status: Approved by FDA References: Maraganore, J.M. et al., Biochemistry, 1990, 29, 7095, (synth, pharmacol) Skrzypczak-Jankun, E. et al., J. Mol. Biol., 1991, 221, 1379, (struct) Pat. Coop. Treaty (WIPO), 1991, 91 02 750 (Biogen); CA, 115, 150383j, (synth, pharmacol) Maraganore, J.M., Adv. Exp. Med. Biol., 1993, 340, 227, (rev) Roemisch, J. et al., Haemostasis, 1993, 23, 249, (pharmacol) Fox, I. et al., Thromb. Haemostasis, 1993, 69, 157, (pharmacol) Johnson, P.H., Annu. Rev. Med., 1994, 45, 165, (rev) Scatena, R., Expert Opin. Invest. Drugs, 2000, 9, 1119-1127, (rev) Carswell, C.I. et al., Drugs, 2002, 62, 841-870, (rev 新人，需鼓励 [ Last edited by 小小强 on 2006-5-18 at 22:37 ] |
回复此楼» 猜你喜欢
关于口服溶液剂药品上市后稳定性研究
已经有2人回复
-
FDA核查 研发机构
已经有1人回复
-
药理学论文润色/翻译怎么收费?
已经有288人回复
-
国家高层次人才李兴淑教授课题组招收博士研究生
已经有39人回复
-
己酮可可碱过氧化杂质限度
已经有2人回复
-
求助Isoeugenol质量标准
已经有0人回复
-
Gliclazide
已经有0人回复
-
塞替派/噻替哌（Thiotepa） 质量控制
已经有12人回复
-
有没有大佬可以帮忙查下Trijardy XR和Qternmet XR历年销售数据呀
已经有0人回复
1
 |
2楼2006-04-27 06:43:27
0.5
 |
3楼2006-04-28 14:38:49